Abstracts Archive - Page 144 of 2607 - ACR Meeting Abstracts

Abstract Number: 0253 • ACR Convergence 2025
Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
Justin Nguyen¹, Philip Bucur², Sai Patel², Aamer Syed², Thomas Iden³, Jessica McLaughlin², Neha Gupta², Jordana Kron², Kelly Gwathmey², Ryan Canissario², Vaishali Patel² and Huzaefah Syed², ¹Virginia Commonwealth University Medial Center, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Medical Center, Richmond
Background/Purpose: Asymptomatic ocular involvement must be considered in any patient with sarcoidosis. If left untreated, severe complications, including vision loss, can occur. As a result,…
Abstract Number: 0254 • ACR Convergence 2025
Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis
Justin Riley Lam¹, Emmanuel Otabor², Laith Alomari², Michael Hamilton², Maxim Barnett², Shahrzad Abdollahi³ and Irene Tan⁴, ¹Albert Einstein Medical Center, Philadelphia, PA, ²Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA, ⁴Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: MAGIC syndrome, a rare overlap of relapsing polychondritis (RP) and Behçet’s disease manifestations, remains poorly characterized compared to isolated RP. Behçet’s-associated features such as…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
Abstract Number: 0263 • ACR Convergence 2025
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Michelle Benjamin¹, Mattia Wruble Clark², Shamik Bhattacharyya³, Audra Horomanski¹ and Kristin Galetta⁴, ¹Stanford University, Palo Alto, CA, ²Mass General Brigham, Somerville, MA, ³Brigham and Women's Hospital, Malden, MA, ⁴Stanford Medical Center, Palo Alto
Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can…
Abstract Number: 0057 • ACR Convergence 2025
TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Rajesh Singh¹, Bindi Patel², Rameshwari Rayaji², Archana Sidalaghatta Nagaraja², Saranya Chandrasekar², Yihong Guan², Ritu Kushwaha², Yue Tong Lee², Cesar Meleza², Matthew Epplin², Brandon Rosen², Manmohan R Leleti², Matthew J Walters² and Daniel DiRenzo², ¹Arcus Biosciences, inc., Santa Clara, CA, ²Arcus Biosciences, inc., Hayward, CA
Background/Purpose: Anti-TNF biologics are effective in the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. However, they can lead to de novo inflammation…
Abstract Number: 0261 • ACR Convergence 2025
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Daphne Guinn¹, Linchen He², Yuru Ren¹, Valeriy Korostyshevskiy¹ and Robert Beckman¹, ¹Georgetown University, Washington, ²Novartis, East Hanover
Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Jacopo Mora¹, Francesca Regola¹, Paola Toniati², Giulia Fontana¹, Alessia Gatti¹, Ilaria Cavazzana³ and Franco Franceschini⁴, ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ³Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁴University of Brescia, Brescia, Brescia, Italy
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…
Abstract Number: 0276 • ACR Convergence 2025
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Thomas Pelowitz, Benjamin Hur, Kenneth Warrington, Jaeyun Sung and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease of the retroperitoneum that can lead to obstructive uropathy and other life-threatening complications. While RPF can…
Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Xiwei Yang¹, Shae Chambers², Aretha On¹, Hammad Ali², Touraj Khosravi³, Lais Lopes Almeida Gomes², Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…
Abstract Number: 0189 • ACR Convergence 2025
“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists
Megan Creasman¹, Jing Li², Augusto Garcia-Agundez³, gabriela Schmajuk⁴ and Jinoos Yazdany³, ¹UC San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Heavy documentation contributes to clinician workload and burnout. Rheumatology carries one of the highest documentation burdens among Internal Medicine (IM) subspecialties. While recent advances…
Abstract Number: 0218 • ACR Convergence 2025
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Ross Gilbert¹, Starla Blanks², Joy Buie³, Mary Cronin⁴, Jake Decker⁵, Laura Dickmann⁶, Cristina Drenkard⁷, Sancia Ferguson⁸, Shivani Garg⁹, David Gazeley⁵, Andrea Gilmore-Bykovskyi¹⁰, Gale Johnson¹¹, Patti Katz¹², Tristan Lazewski¹³, S. Sam Lim¹⁴, Jenna McGoldrick¹⁵, Katrina Phelps¹⁰, Edmond Ramly¹⁶, Rosalind Ramsey-Goldman¹⁷, Ann Rosenthal¹⁸, Dawn Thomas-Semanko¹⁹, Sarah Stoltz¹³, Patricia Tellez-giron²⁰, Amannda Weber²¹, Andrea Wipperfurth¹³ and Christie Bartels¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²American College of Rheumatology, Atlanta, GA, ³Lupus Foundation of America, Washington, DC, ⁴retired, Fox Point, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert Health, Waukesha, WI, ⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, ⁸University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹Wisconsin Department of Health Services, Madison, WI, ¹²UCSF, San Rafael, CA, ¹³UW Health, Madison, WI, ¹⁴Emory University School of Medicine, Atlanta, GA, ¹⁵SSM Health, Madison, WI, ¹⁶Indiana University - Bloomington, Bloomington, IN, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, ¹⁹WI Chapter - LFA, Milwaukee, WI, ²⁰University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²¹University of Wisconsin (UW), UW Health, Madison, WI
Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].